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Abstract 
Background: The aim of this study is to explore the expression of alpha-synuclein (α-synuclein) in benign, atypical, 
and anaplastic meningiomas and determine its role in the malignant progression of meningiomas.
Methods: Expression of α-synuclein was measured in 44 meningioma samples by real-time PCR analysis. The effects 
of overexpression or knockdown of α-synuclein on meningioma cell growth, invasiveness, and tumorigenicity were 
determined.
Results: Atypical and anaplastic meningiomas displayed significantly greater levels of α-synuclein mRNA, relative 
to benign tumors. Depletion of α-synuclein decreased cell proliferation and colony formation and promoted apop-
tosis in IOMM-Lee meningioma cells, whereas overexpression of α-synuclein facilitated cell proliferation and colony 
formation in CH-157MN meningioma cells. Silencing of α-synuclein attenuated IOMM-Lee cell migration and inva-
sion. In contrast, ectopic expression of α-synuclein increased the invasiveness of CH-157MN cells. In vivo studies 
further demonstrated that downregulation of α-synuclein significantly retarded meningioma growth in nude mice. 
At the molecular level, the phosphorylation levels of Akt, mTOR, p70S6K and 4EBP were significantly decreased in 
α-synuclein-depleted IOMM-Lee cells.
Conclusions: In conclusion, α-synuclein upregulation contributes to aggressive phenotypes of meningiomas via the 
Akt/mTOR pathway and thus represents a potential therapeutic target for malignant meningiomas.
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Background
Meningiomas are mesenchymal tumors that account for 
~30% of all primary intracranial tumors [1]. Most menin-
giomas are benign tumors of World Health Organization 
(WHO) grade I. However, up to 20% of meningiomas 
have aggressive behaviors, which are classified as atypical 
WHO grade II or anaplastic WHO grade III [2]. The Akt/
mTOR pathway has been suggested to be involved in the 
pathogenesis of meningiomas [3, 4]. However, the molec-
ular mechanisms underlying the malignant progression 
of meningiomas are still elusive.
Alpha-synuclein (α-synuclein) is a soluble presynap-
tic protein belonging to the synuclein protein family. It 
is well known that α-synuclein can form insoluble fibril 
aggregates and play a pathogenic role in Parkinson’s dis-
ease (PD) [5]. In addition to expression in nervous tis-
sues, α-synuclein is expressed in other tissue types such 
as melanomas [6–8]. It was found that α-synuclein is 
abundantly presented in primary and metastatic mela-
nomas, but undetectable in non-melanocytic cutane-
ous carcinoma and normal skin [6]. There is evidence 
that α-synuclein differentially regulates the synthesis 
of melanin in melanoma and dopaminergic neuronal 
cells, consequently affecting cell susceptibility to ultra-
violet radiation-induced injury [8]. A previous study has 
demonstrated that α-synuclein is expressed in a vari-
ety of brain tumors, but not in benign meningiomas 
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[9]. However, the expression and biological relevance of 
α-synuclein in the malignant progression of meningi-
omas are not clarified.
In this study, we compared the expression of 
α-synuclein in atypical and anaplastic meningiomas ver-
sus benign tumors and explored the roles of α-synuclein 
in regulating the aggressive phenotypes of meningiomas.
Methods
Tissue samples
A total of 44 meningioma specimens (18 benign, 17 atyp-
ical, and 9 anaplastic meningiomas) were obtained from 
patients who underwent surgery at Department of Neu-
rosurgery of Shanghai University of Traditional Chinese 
Medicine (Shanghai, China). Tumor tissues were imme-
diately frozen in liquid nitrogen and stored at −80  °C 
until analysis. All cases were pathologically diagnosed. 
Tumors were classified according to the 2007 WHO clas-
sification system [10].
Cell culture
Primary human meningeal cells were purchased from 
ScienCell (Carlsbad, CA, USA). IOMM-Lee and CH-
157MN meningioma cell lines were obtained from the 
Shanghai Institute of Cell Research (Shanghai, China). 
Cells were cultured in high-glucose Dulbecco’s modified 
Eagle medium (DMEM) with 10% fetal bovine serum 
(FBS), 100 μg/mL streptomycin, and 100 U/mL penicillin 
(Invitrogen, Carlsbad, CA, USA).
Quantitative real‑time PCR (qRT‑PCR) analysis
Total RNA from tumor tissues and cells was extracted 
using TRIzol reagent (Takara, Dalian, China) following 
the manufacturer’s protocol. Reverse transcription was 
completed with random primers using the Superscript 
III Reverse Transcriptase Kit (Invitrogen, Carlsbad, CA, 
USA). Real-time PCR was performed on an ABI7900 
Real-Time PCR System (Applied Biosystems, Foster City, 
CA, USA) using SYBR Green RT-PCR kit (QIAGEN, 
Valencia, CA, USA). The PCR primers are as follows [11]: 
α-synuclein: forward, 5′-GCCAAGGAGGGAGTTGTGG 
CTGC-3′ and reverse, 5′-CTGTTGCCACACCATGCAC 
CACTCC-3′; β-actin: forward, 5′-TCTACAATGAGCTG 
CGTGTG-3′ and reverse, 5′-GGTGAGGATCTTCATGA 
GGT-3′. The relative α-synuclein mRNA level was deter-
mined after normalization against that of β-actin.
Plasmids and transfections
Small hairpin RNA (shRNA) targeting human 
α-synuclein gene and negative control shRNA were pur-
chased from Santa Cruz Biotechnology (Santa Cruz, CA, 
USA). For generation of α-synuclein-expressing plasmid, 
full-length human α-synuclein cDNA was amplified by 
PCR and cloned into pcDNA3.1(+) vector (Invitrogen). 
Cell transfections were performed using HiPerfect Trans-
fection reagent (Qiagen, Hilden, Germany). After incuba-
tion for 24 h, cells were subjected to further analyses. For 
generation of stable clones, IOMM-Lee cells transfected 
with α-synuclein shRNA or control shRNA were selected 
with puromycin (2 μg/mL; Sigma-Aldrich) for 3 days.
BrdU incorporation assay
Cell proliferation was assessed by 5-bromo-2′-deoxyuridine 
(BrdU) incorporation assay using the Cell Proliferation 
ELISA, BrdU (colorimetric) kit (Roche Applied Science, 
Indianapolis, IN, USA). In brief, cells were labeled using 
10  μM BrdU and incubated overnight at 37  °C. The cells 
were then fixed and re-incubated with anti-BrdU antibody 
for 2  h at room temperature. The substrate solution was 
added and the reaction product was quantified by measur-
ing the absorbance at 450 nm.
Apoptosis analysis
For analysis of apoptosis, cells were fixed in 70% ethanol 
and incubated with propidium iodide and Annexin-V for 
30 min. Stained cells were analyzed on a flow cytometer 
(Becton–Dickinson Biosciences, San Jose, CA, USA).
Colony formation assay
Transfected cells were seeded onto six-well plates at a 
low density (600 cell per well) and cultured for 10 days. 
Colonies were fixed, stained with 0.1% crystal violet 
(Sigma-Aldrich), and counted.
In vitro wound‑healing assay
Cell migration capacity was evaluated using in  vitro 
wound-healing assay, as described previously [12]. In 
brief, cells were seeded onto six-well plates and allowed 
to grow to confluence. The cell monolayer was scratched 
with a 100-μL pipette tip. After washing, the cell culture 
was incubated for 24  h. The percentage of wound clo-
sure was determined under a microscope. This assay was 
repeated three times.
Transwell invasion assay
Cells in serum-free medium (1  ×  105 cells/well) were 
plated onto the upper chamber pre-coated with Matrigel 
(Becton–Dickinson Biosciences). The lower chamber was 
added with DMEM containing 10% FBS. After incuba-
tion for 24 h, cells that had invaded through the Matrigel 
were stained with 0.1% crystal violet and counted.
Animal experiments
Eight 6–8-week-old nude mice (Shanghai Laboratory 
Animal Center, Chinese Academy of Sciences, Shanghai, 
China) were used for tumorigenic studies. IOMM-Lee 
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cells stably transfected with α-synuclein shRNA or con-
trol shRNA were subcutaneously injected into nude mice 
(n = 4; 4 × 106 cells/mouse). Tumor volume was deter-
mined every 5 days. At 25 days after cell injection, mice 
were sacrificed and xenograft tumors were removed and 
weighed.
Western blot analysis
Protein extracts from tumor tissues and cells were pre-
pared in radioimmunoprecipitation assay (RIPA) buffer 
containing protease inhibitors (Sigma-Aldrich). Protein 
samples were separated by sodium dodecyl sulphate–
polyacrylamide gel electrophoresis and transferred onto 
nitrocellulose membranes. Primary antibodies (1:500 
dilution) used here are as follows: anti-Akt, anti-Akt 
(ser473), anti-mTOR, anti-phospho-mTOR (Ser2448), 
anti-phospho-p70S6K1 (Thr389), anti-p70S6K1, anti-
phospho-4EBP (Thr37/46), anti-4EBP (Cell Signal-
ing Technology, Beverly, MA, USA), anti-α-synuclein 
(Abcam, Cambridge, MA, USA), and anti-β-actin 
(Sigma-Aldrich). Blots were developed with an enhanced 
chemiluminescence system (GE Healthcare Biosciences, 
Piscataway, NJ, USA). Densitometric analysis of the blots 
were performed using the Quantity One software (Bio-
Rad Laboratories, Richmond, CA, USA).
Statistical analysis
Data are presented as mean  ±  standard deviation and 
were analyzed by the Student’s t test or one-way analy-
sis of variance followed by Tukey post hoc test. The 
Mann–Whitney U test was used to analyze differences of 
α-synuclein expression in benign, atypical, and anaplastic 
meningiomas. P values  < 0.05 were considered statisti-
cally significant.
Results
Upregulation of α‑synuclein in atypical and anaplastic 
meningiomas
To check the involvement of α-synuclein in meningioma 
progression, we examined its expression in 44 meningi-
oma samples. qRT-PCR analysis showed increased abun-
dance of α-synuclein mRNA in atypical (P  =  0.0067) 
and anaplastic (P =  0.0035) meningiomas (Fig.  1a). We 
also measure the level of α-synuclein in human malig-
nant meningioma cell lines. The mRNA expression of 
α-synuclein was significantly increased in IOMM-Lee 
cells and to a greater extent in CH-157MN cells, when 
compared to primary meningeal cells (P < 0.05; Fig. 1b). 
Therefore, in this study, IOMM-Lee cells were used 
in α-synuclein knockdown experiments, while CH-
157MN cells were used in α-synuclein overexpression 
experiments.
Knockdown of α‑synuclein reduces cell proliferation 
and colony formation and increases apoptosis 
in IOMM‑Lee meningioma cells
To determine the biological significance of α-synuclein 
dysregulation in meningioma, RNA interfering tech-
nology was employed to knock down its expression. As 
shown in Fig. 2a, delivery of specific α-synuclein shRNA 
resulted in about 85% decline in α-synuclein mRNA 
levels in IOMM-Lee cells (P  <  0.05 vs. control shRNA-
transfected cells). Consistently, the α-synuclein protein 
levels were also decreased in IOMM-Lee cells transfected 
with α-synuclein shRNA (Fig.  2a). Downregulation of 
α-synuclein inhibited cell proliferation by 42% in IOMM-
Lee cells, as determined by BrdU incorporation assay 
(Fig. 2b). Colony formation assays further demonstrated 
that knockdown of α-synuclein led to a 65% reduction 
in the number of colonies after incubation for 10  days 
(Fig.  2c). Additionally, the percentage of apoptotic cells 
was significantly greater in the α-synuclein shRNA group 
than in the control shRNA group (26.9  ±  2.3% vs. 4. 
8 ± 1.2%, P < 0.05; Fig. 2d).
Silencing of α‑synuclein attenuates IOMM‑Lee cell 
migration and invasion
Next, we investigated the effect of silencing of 
α-synuclein on the migration and invasion of IOMM-
Lee cells. Wound-healing assay demonstrated that the 
percentage of wound closure was significantly lower 
in the α-synuclein-depleted group than in the con-
trol group, after incubation for 48 h (P < 0.05; Fig. 3a). 
Fig. 1 Upregulation of α-synuclein in atypical and anaplastic menin-
giomas. a qRT-PCR analysis of α-synuclein mRNA in benign, atypical, 
and anaplastic meningiomas. b Measurement of α-synuclein mRNA 
in normal meningeal cells and IOMM-Lee and CH-157MN meningi-
oma cells. *P < 0.05 versus normal meningeal cells
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Transwell invasion assay showed that the number of 
invaded cells was reduced by 44% after transfection 
with α-synuclein shRNA, compared with the control 
group (P  <  0.05; Fig.  3b). These results indicate that 
α-synuclein is implicated in the invasiveness of menin-
gioma cells.
The Akt/mTOR pathway is inhibited 
in α‑synuclein‑depleted IOMM‑Lee cells
At the molecular level, we noted that the phosphoryla-
tion levels of mTOR and its substrates p70S6K and 4EBP, 
as well as Akt were significantly reduced in α-synuclein-
depleted IOMM-Lee cells (Fig.  4). However, total 
amounts of mTOR, p70S6K, 4EBP, and Akt protein were 
not altered by α-synuclein silencing.
Overexpression of α‑synuclein promotes CH‑157MN cell 
growth and invasion
To complement the knockdown experiments, overex-
pression studies were also conducted. Enforced expres-
sion of α-synuclein (Fig. 5a) was found to accelerate cell 
proliferation (Fig.  5b) and colony formation (Fig.  5c) in 
CH-157MN meningioma cells. Moreover, α-synuclein-
overexpressing CH-157MN cells exhibited a 2.1-fold 
increase in invasiveness, compared to empty vector-
transfected cells (Fig. 5d). These observations underscore 
Fig. 2 Knockdown of α-synuclein (α-Syn) reduces cell proliferation and colony formation and increases apoptosis in meningioma cells. a Measure-
ment of α-Syn mRNA and protein levels in IOMM-Lee meningioma cells transfected with control or α-Syn shRNA. b BrdU incorporation assay was 
performed to determine cell proliferation in IOMM-Lee cells transfected with control or α-Syn shRNA. c Colony formation assay. IOMM-Lee cells 
transfected with control or α-Syn shRNA were allowed to form colonies for 10 days. Top representative dishes. Bottom quantification of colony for-
mation. d Apoptosis was quantified by flow cytometry. Top representative dot plots of cells stained with Annexin-V and PI. Bottom quantitative data 
from three independent experiments. *P < 0.05 versus cells transfected with control shRNA
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the importance of α-synuclein in the aggressiveness of 
meningioma cells.
Depletion of α‑synuclein retards tumor growth in a mouse 
xenograft model
Finally, we studied in vivo therapeutic potential of deple-
tion of α-synuclein in controlling meningioma growth. 
To this end, IOMM-Lee cells stably transfected with 
α-synuclein shRNA or control shRNA were subcuta-
neously injected into nude mice, and tumor growth 
was assessed. Notably, α-synuclein-depleted IOMM-
Lee cells formed significantly smaller xenograft tumors 
from 10  days after cell injection (Fig.  6a). Final tumor 
weight was only 38% of the control group (P  <  0.05; 
Fig.  6b). Immunohistochemical analysis confirmed that 
α-synuclein-depleted tumors had a significantly lower 
percentage of Ki-67-positive cells than control counter-
parts (P < 0.05; Fig. 6c).
Discussion
Members of the synuclein family have been associated 
with the development of certain tumors [13]. It was 
reported that γ-synuclein expression is dysregulated in 
oral squamous cell carcinoma [14], esophageal cancer 
[15], and breast cancer [16]. The α-synuclein protein 
shows distinct tissue distributions and is predominantly 
expressed in brain tumors and melanomas [8, 9, 17]. 
In agreement with a previous study [9], we found that 
α-synuclein expression was very low in benign meningi-
omas. However, an increased expression of α-synuclein 
was observed in atypical and anaplastic meningiomas, 
suggesting its implication in the malignant progression of 
meningiomas.
To explore the biological relevance of α-synuclein 
upregulation, we performed loss- and gain-of-function 
studies. The results showed that downregulation of 
α-synuclein inhibited cell proliferation and colony for-
mation in IOMM-Lee meningioma cells, whereas over-
expression of α-synuclein led to opposite outcomes in 
CH-157MN meningioma cells. Moreover, knockdown 
of α-synuclein significantly triggered apoptotic death in 
IOMM-Lee cells, suggesting that α-synuclein is required 
for the growth and survival of meningioma cells. In vivo 
studies confirmed that α-synuclein contributes to tumo-
rigenicity of meningioma cells. It has been documented 
that extracellular α-synuclein at nanomolar concentra-
tions promotes dopaminergic neuronal survival [18]. 
However, secreted α-synuclein from SH-SY5Y neuro-
blastoma cells exert detrimental effects on the survival 
of recipient neuronal cells [19]. Another study dem-
onstrated that overexpression of α-synuclein causes 
non-apoptotic death in human neuronal cells [20]. 
These studies, combined with our findings, suggest that 
α-synuclein has distinct roles in the regulation of cell sur-
vival in different biological settings.
In addition to regulation of cell proliferation and sur-
vival, our data showed that α-synuclein also modu-
lates the migration and invasion of meningioma cells. 
We observed that α-synuclein silencing suppressed 
the motility and invasiveness of IOMM-Lee meningi-
oma cells. In contrast, overexpression of α-synuclein 
Fig. 3 Silencing of α-synuclein (α-Syn) attenuates IOMM-Lee cell 
migration and invasion. a In vitro wound-healing assay. IOMM-Lee 
cells transfected with control or α-Syn shRNA were subjected to 
in vitro wound-healing assay. Left representative images of wounded 
monolayers at 0 and 48 h after scratching. Right quantitative data 
from three independent experiments. b Transwell invasion assay. Left 
representative images of cells that invaded through the Matrigel-
coated insert. Right quantitative data from three independent experi-
ments. *P < 0.05 versus cells transfected with control shRNA
Fig. 4 The Akt/mTOR pathway is inhibited in α-synuclein (α-Syn)-
depleted cells. Western blot analysis of indicated proteins in IOMM-
Lee cells transfected with control or α-Syn shRNA. Left representative 
Western blots from three independent experiments. Right quantita-
tive analysis of the phosphorylated/total protein levels. *P < 0.05
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facilitated the invasion of CH-157MN meningioma cells. 
The pro-invasive capacity of α-synuclein provides a bio-
logical explanation for its upregulation in atypical and 
anaplastic meningiomas. Although there is few evidence 
for α-synuclein-mediated cell invasiveness, γ-synuclein 
has been shown to promote cell migration and invasion 
in different types of tumor cells such as oral squamous 
cell carcinoma [12], breast cancer [21], and gastric cancer 
[22].
Activation of the Akt/mTOR pathway is involved in 
the development and progression of meningioma [3, 4]. 
Fibroblast growth factor receptor-3 was found to induce 
the proliferation of meningioma cells via activation of 
the phosphoinositide 3 kinase-Akt-PRAS40-mTOR 
and STAT3 pathways [23]. Pharmacological inhibi-
tion of mTOR signaling was reported to impair menin-
gioma growth in mouse models [24]. Inhibition of Akt 
activation accounts for growth reduction and apoptosis 
induction by depletion of astrocyte elevated gene-1 in 
human meningioma cells [25]. Notably, our data showed 
that α-synuclein silencing significantly decreased the 
phosphorylation of Akt, mTOR, p70S6K, and 4EBP in 
IOMM-Lee cells, which provides a mechanistic explana-
tion for the regulation of aggressive phenotypes of men-
ingioma cells by α-synuclein.
Conclusions
In conclusion, α-synuclein is upregulated in atypical and 
anaplastic meningiomas compared to benign tumors and 
α-synuclein upregulation contributes to the aggressive 
behavior of meningioma cells via the Akt/mTOR path-
way. Thus, α-synuclein represent a potential therapeutic 
target against malignant meningiomas.
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